Raludotatug deruxtecan

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody drug conjugate
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody drug conjugate
www.ebi.ac.uk
Drug name
Raludotatug deruxtecan
www.ebi.ac.uk

  • ds 6000a
  • Ds 6000a
  • DS-6000a
  • DS-6000A
  • ds6000a
  • DS6000A
  • gamma1 heavy chain humanized (1-452) [VH (Homo sapiens IGHV1-3*01 (86.7%)-(IGHD)-IGHJ4*01(93.3%), CDR-IMGT [8.8.15] (26-33.51-58.97-111))(1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (219)(123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo sapiens IGKV1-39*01 (86%) -IGKJ1*01 (91.7%), CDR-IMGT[6.3.8] (27-32.50-52.89-96)) (1'-106')-Homo sapiens IGKC*01 (100%), Km3 A45.1 (152), V101(190) (107'-213')]; dimer (231-231'': 234-234'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; conjugated, on an average of 8 cysteinyl, to deruxtecan, comprising a linker and a camptothecin derivative
  • gamma1 heavy chain humanized 1 452 vh homo sapiens ighv1 3 01 86 7 ighd ighj4 01 93 3 cdr imgt 8 8 15 26 33 51 58 97 111 1 122 homo sapiens ighg1 03 g1m3 ng1m1 ch1 r120 219 123 220 hinge 1 15 221 235 ch2 236 345 ch3 e12 361 m14 363 346 450 chs 451 452 123 452 225 213 disulfide with kappa light chain humanized 1 213 v kappa homo sapiens igkv1 39 01 86 igkj1 01 91 7 cdr imgt 6 3 8 27 32 50 52 89 96 1 106 homo sapiens igkc 01 100 km3 a45 1 152 v101 190 107 213 dimer 231 231 234 234 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa conjugated on an average of 8 cysteinyl to deruxtecan comprising a linker and a camptothecin derivative
  • immunoglobulin g1 anti human g cadherin 6 human rattus norvegicus monoclonal mabu 9014a γ1 chain complex with human rattus norvegicus monoclonal mabu 9014a κ chain dimer octakis thioether with n 6 3 mercapto 2 5 dioxo 1 pyrrolidinyl 1 oxohexyl glycylglycyl l phenylalanyl n 2 1s 9s 9 ethyl 5 fluoro 2 3 9 10 13 15 hexahydro 9 hydroxy 4 methyl 10 13 dioxo 1h 12h benzo de pyrano 3 4 6 7 indolizino 1 2 b quinolin 1 yl amino 2 oxoethoxy methyl glycinamide
  • immunoglobulin g1 kappa anti homo sapiens cdh6 cadherin 6 k cadherin foetal kidney cadherin 6 type 2 humanized monoclonal antibody conjugated to deruxtecan comprising a linker and a camptothecin derivative
  • immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative
  • Immunoglobulin G1, anti-(human G cadherin 6) (human-Rattus norvegicus monoclonal MABU-9014a γ1-chain), complex with human-Rattus norvegicus monoclonal MABU-9014a κ-chain, dimer, octakis(thioether) with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide
  • RALUDOTATUG DERUXETCAN [USAN]
  • raludotatug deruxetcan usan
  • raludotatug deruxtecan
  • Raludotatug deruxtecan
  • Raludotatug Deruxtecan
  • Raludotatug Deruxtecan (R-DXd)
  • raludotatug deruxtecan [INN]
  • Raludotatug deruxtecan [WHO-DD]
  • raludotatug deruxtecan inn
  • raludotatug deruxtecan who dd

CAS registry numbers
  • 2610074-57-0
ChEMBL ID
CHEMBL5095329
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • BPQ010OFD7

First in class
No
Orphan designation
No

Pharmacology name
raludotatug deruxtecan
Type
Antibody
Drug name stem
-tecan

Mechanisms of action

  • Action
    Binding
    Action type
    Binding
    Target
    cadherin 6
    Gene symbol
    CDH6
    Protein identifier
    P55285

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0002158
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0002974
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005005
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005086
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0008170
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0008433
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0011962
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0015686
    Highest recorded phase
    2

Prodrug
No
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23''''-88''' $ 133'-193' $ 133'''-193''' $ 149-205 $ 149''-205'' $ 225-213' $ 225''-213''' $ 231-231'' $ 234-234'' $ 266-326 $ 266''-326'' $ 372-430 $ 372''-430''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    302 $ 302''

Related records

Trials (11)

In development for (1)